Clinical Trials
21 trialsNCT00875056 2026-01-30
MK-0683-103
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01728805 2024-04-25
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00127127 2022-09-13
MK-0683-029
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00858234 2021-04-09
MK-0683-098
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00773838 2021-04-01
MK-0683-095
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00642954 2020-11-18
MK-0683-074
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00128102 2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00423449 2016-02-04
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00479232 2015-09-21
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00373490 2015-08-27
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00632931 2015-07-30
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00473889 2015-07-03
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00111813 2015-05-21
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00907738 2015-05-21
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00127101 2015-04-21
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00771472 2015-04-21
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00424775 2015-04-20
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00251589 2015-03-06
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00106626 2009-04-22
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1 Completed